These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 36701817

  • 1. Clinical pharmacology of SGLT-2 inhibitors in heart failure.
    Velliou M, Polyzogopoulou E, Ventoulis I, Parissis J.
    Expert Rev Clin Pharmacol; 2023 Feb; 16(2):149-160. PubMed ID: 36701817
    [Abstract] [Full Text] [Related]

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S.
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [Abstract] [Full Text] [Related]

  • 3. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M, D'Amario D, Sofia C, Vaccarella M, Crea F, Aspromonte N.
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [Abstract] [Full Text] [Related]

  • 4. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients.
    Nakagawa Y, Kuwahara K.
    J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780
    [Abstract] [Full Text] [Related]

  • 5. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
    Green JB, McCullough PA.
    Cardiorenal Med; 2022 Aug; 12(3):81-93. PubMed ID: 35835083
    [Abstract] [Full Text] [Related]

  • 6. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
    Ji PJ, Zhang ZY, Yan Q, Cao HL, Zhao YJ, Yang B, Li J.
    ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
    [Abstract] [Full Text] [Related]

  • 7. Growing role of SGLT2i in heart failure: evidence from clinical trials.
    Varadhan A, Stephan K, Gupta R, Vyas AV, Ranchal P, Aronow WS, Hawwa N, Lanier GM.
    Expert Rev Clin Pharmacol; 2022 Feb; 15(2):147-159. PubMed ID: 35264076
    [Abstract] [Full Text] [Related]

  • 8. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY, Brooksbank KJM, Wetherall K, Mangion K, Roditi G, Campbell RT, Berry C, Chong V, Coyle L, Docherty KF, Dreisbach JG, Labinjoh C, Lang NN, Lennie V, McConnachie A, Murphy CL, Petrie CJ, Petrie JR, Speirits IA, Sourbron S, Welsh P, Woodward R, Radjenovic A, Mark PB, McMurray JJV, Jhund PS, Petrie MC, Sattar N.
    Circulation; 2021 Feb 09; 143(6):516-525. PubMed ID: 33186500
    [Abstract] [Full Text] [Related]

  • 9. SGLT2 inhibitors for heart failure with reduced ejection fraction: a real EMPEROR?
    Raschi E, Fadini GP, Diemberger I, Poluzzi E, De Ponti F.
    Expert Opin Pharmacother; 2021 Apr 09; 22(5):647-650. PubMed ID: 33141609
    [Abstract] [Full Text] [Related]

  • 10. Systematic Review of the Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors Used as Treatment in Patients with Heart Failure.
    Nam K, Cho DS, Kim H, Kwon B, Yoon Y, Park C, Kim ES, Youn JC, Park SK.
    Clin Drug Investig; 2023 Jul 09; 43(7):463-474. PubMed ID: 37365452
    [Abstract] [Full Text] [Related]

  • 11. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.
    Long A, Salvo M.
    Ann Pharmacother; 2024 Sep 09; 58(9):935-946. PubMed ID: 38014844
    [Abstract] [Full Text] [Related]

  • 12. SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?
    Pabel S, Hamdani N, Luedde M, Sossalla S.
    Curr Heart Fail Rep; 2021 Oct 09; 18(5):315-328. PubMed ID: 34523061
    [Abstract] [Full Text] [Related]

  • 13. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
    Jhalani NB.
    Adv Ther; 2022 Aug 09; 39(8):3472-3487. PubMed ID: 35699903
    [Abstract] [Full Text] [Related]

  • 14. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction.
    De Lorenzi AB, Kaplinsky E, Zambrano MR, Chaume LT, Rosas JM.
    Drugs Context; 2023 Aug 09; 12():. PubMed ID: 36660013
    [Abstract] [Full Text] [Related]

  • 15. SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms.
    Nikolic M, Zivkovic V, Jovic JJ, Sretenovic J, Davidovic G, Simovic S, Djokovic D, Muric N, Bolevich S, Jakovljevic V.
    Heart Fail Rev; 2022 May 09; 27(3):935-949. PubMed ID: 33534040
    [Abstract] [Full Text] [Related]

  • 16. Beneficial cardiovascular and remodeling effects of SGLT 2 inhibitors.
    Chrysant SG, Chrysant GS.
    Expert Rev Cardiovasc Ther; 2022 Mar 09; 20(3):223-232. PubMed ID: 35320057
    [Abstract] [Full Text] [Related]

  • 17. Egyptian expert opinion for the use of sodium-glucose cotransporter-2 inhibitors in patients with heart failure with reduced ejection fraction.
    Abdelhamid M, Kandil H, Hassanin M, Shaheen S, Sobhy M, ElEtreby A, Hasan-Ali H, Mahfouz H, Nasr G, Shawky I, Emil S, ElSetiha M, Hasssan M, Sadek Y, Karim MA, Asham A, Ghaleb M, Samir A, Shokry K.
    ESC Heart Fail; 2022 Apr 09; 9(2):800-811. PubMed ID: 35118822
    [Abstract] [Full Text] [Related]

  • 18. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
    Aguilar-Gallardo JS, Correa A, Contreras JP.
    Eur Heart J Cardiovasc Pharmacother; 2022 May 05; 8(3):311-321. PubMed ID: 34264341
    [Abstract] [Full Text] [Related]

  • 19. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G, Brueckmann M, Ofstad AP, Pfarr E, Jamal W, Packer M.
    Lancet; 2020 Sep 19; 396(10254):819-829. PubMed ID: 32877652
    [Abstract] [Full Text] [Related]

  • 20. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
    Nassif ME, Kosiborod M.
    Diabetes Obes Metab; 2019 Apr 19; 21 Suppl 2():19-23. PubMed ID: 31081589
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.